Asian Chip Stocks Mixed After Nvidia Earnings Beat 
Hong Kong Home Prices Fall 0.5% in July, Ending Long Winning Streak 
Bank of Korea Raises Rates to 3% as Inflation Stays Sticky 
BOJ’s Himino Signals Timely Rate Hikes as Inflation Risks Rise 
Asian Stocks Mixed as KOSPI Falls Ahead of Fed Speech 
Gold Prices Tumble 3% After Hawkish Fed Speech Boosts Dollar 
Canadian Dollar Slides as Fed Rate Hike Bets Boost US Dollar 
Dollar Steady Ahead of Jackson Hole as Yen Holds Firm 
Bessent Defends US Yen Intervention Over Treasury Market Risks 
Gold Prices Rise Toward $4,650 Ahead of Warsh’s Jackson Hole Speech 
German Industry Pushes Merz for Tougher China Trade Policy 
Oil Prices Slip as Venezuela Supply Prospects Weigh on Market 
Japan Firms Ramp Up Yen Hedging as Currency Weakness Persists 
US Dollar Hits Two-Week High After Hawkish Fed Speech 
Oil Prices Slip on Venezuela Supply, Iran Tensions 
Sweden Retail Sales Slip 0.2% in July 
Asian Currencies Steady Ahead of Warsh Speech 
Add as a preferred source on Google
China has approved Eli Lilly’s Kisunla, marking another milestone in global efforts to address Alzheimer’s disease. The treatment, designed to slow memory decline and clear brain plaques, offers early-stage patients a unique dosing approach and new hope for managing the disease.
China Approves Kisunla as a New Alzheimer's Treatment Option
After Eisai and Biogen's Leqembi were approved in January, Eli Lilly said late Tuesday that their treatment for early Alzheimer's has been approved by China's medical authorities, giving patients another alternative, Reuters reports.
According to a statement from Lilly, the medication, which is marketed under the trade name Kisunla, has been approved in four key markets: the US, Japan, and the UK. The latest addition to this list is China.
In the same way as Leqembi removes beta-amyloid from the brain, Lilly's Kisunla does the same.
Kisunla Shows Promising Results in Cognitive Decline
Kisunla shown a 29% reduction in the development of cognitive impairments as compared to a placebo in a large, late-stage experiment. Although most occurrences were moderate, it did induce brain edema in approximately 25% of patients and brain bleeding in approximately 33%.
In the United States, the prescribing label for Kisunla bears the FDA's most severe "boxed" safety warning, which, like Leqembi, warns of the possibility of fatal brain enlargement and hemorrhage.
Gradual Dosing and Finite Treatment Benefit Kisunla Users
However, the business reported that the number of patients having potentially significant brain swelling was reduced when Kisunla was started on a more gradual dose schedule.
Another advantage of Kisunla over Leqembi is its finite dosage, which lets patients discontinue treatment once brain scans reveal no more amyloid plaques.
The medicines authority of the European Union is presently evaluating the treatment. In July, the body decided against using Leqembi because the potential for severe brain swelling was not worth the minimal benefit in preventing cognitive loss, Investing.com shares.
Alzheimer’s Drives Majority of Dementia Cases Globally
The World Health Organization reports that between sixty percent and seventy percent of dementia cases are caused by Alzheimer's disease.
